These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31860013)

  • 1. CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy.
    Kunchok A; Zekeridou A; Pittock S
    JAMA Neurol; 2020 Feb; 77(2):255-256. PubMed ID: 31860013
    [No Abstract]   [Full Text] [Related]  

  • 2. Glazed (vision) and confused.
    Moss HE; Liu GT; Dalmau J
    Surv Ophthalmol; 2010; 55(2):169-73. PubMed ID: 19804892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab and Its Many Uses.
    Saleh N; Copur MS
    Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469902
    [No Abstract]   [Full Text] [Related]  

  • 4. Keytruda Crosses First-Line Finish Line First.
    Reinke T
    Manag Care; 2017 May; 26(5):24. PubMed ID: 28661847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
    Gadgeel SM; Pennell NA; Fidler MJ; Halmos B; Bonomi P; Stevenson J; Schneider B; Sukari A; Ventimiglia J; Chen W; Galasso C; Wozniak A; Boerner J; Kalemkerian GP
    J Thorac Oncol; 2018 Sep; 13(9):1393-1399. PubMed ID: 29775808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case of dermatomyositis during treatment with pembrolizumab for lung cancer.
    Hinogami H; Yamashita C; Tanaka A; Shirai H; Nakano Y; Matsuura Y
    J Dermatol; 2019 Nov; 46(11):e430-e432. PubMed ID: 31215668
    [No Abstract]   [Full Text] [Related]  

  • 7. Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report.
    Nakano Y; Koide N; Koyama Y; Nitta K; Koizumi T
    Thorac Cancer; 2021 Feb; 12(4):557-559. PubMed ID: 33350050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
    Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F
    Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraneoplastic chorea caused by anti-CRMP5 antibodies associated with small cell lung cancer.
    Jiménez Caballero PE
    Neurologia; 2014 Sep; 29(7):446-7. PubMed ID: 23582747
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential.
    Armstrong SA; Liu SV
    Adv Ther; 2019 Aug; 36(8):1826-1832. PubMed ID: 31209697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report.
    Lee J; Shin JY; Lee JS; Lee SC; Hong MH; Lee CS
    Ocul Immunol Inflamm; 2020 Aug; 28(6):864-867. PubMed ID: 31260339
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.
    Qin Q; Li B
    J Cancer Res Ther; 2019; 15(4):743-750. PubMed ID: 31436226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
    [No Abstract]   [Full Text] [Related]  

  • 16. Advanced non-small cell lung cancer - Treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1423-1432. PubMed ID: 31994619
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung cancer in 2016: immunotherapy comes of age.
    Mitchell PL; John T
    Lancet Respir Med; 2016 Dec; 4(12):947-949. PubMed ID: 27890503
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
    Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The radiographic diagnosis and treatment of paraneoplastic central nervous system disease.
    Glantz MJ; Biran H; Myers ME; Gockerman JP; Friedberg MH
    Cancer; 1994 Jan; 73(1):168-75. PubMed ID: 8275420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.